NAF research grants are for new and innovative studies that are relevant to the cause, pathogenesis or treatment of the hereditary or sporadic ataxias.
Research grants are offered primarily as "seed monies" to assist investigators in the early or pilot phase of their studies and as additional support for ongoing investigations on demonstration of need. It is hoped
that these studies will be further developed to attract future funding from other sources. Grants are awarded for one year only.
The funds granted will be up to $50,000 per award. Applicants for seed-money grants must be faculty members.
Like the Foundation's ongoing Biology of Aging Scholar Awards program, the Neuroscience Scholars program is intended to provide researchers with the support and resources to develop innovative research programs aimed at gaining insight into the fundamental molecular and cellular mechanisms that underlie normal biological function, and when dysfunctional, lead to illness.
The purpose of the BRAIN Initiative Fellows (F32) program is to enhance the research training of promising postdoctorates, early in their postdoctoral training period, who have the potential to become productive investigators in research areas that will advance the goals of the BRAIN Initiative. Applications are encouraged in any research area that is aligned with the BRAIN Initiative, including neuroethics. Applicants are expected to propose research training in an area that complements their predoctoral research. Formal training in quantitative perspectives and analytical tools is expected to be an integral part of the proposed research training plan. In order to maximize the training potential of the F32 award, this program encourages applications from individuals who have not yet completed their terminal doctoral degree and who expect to do so within 12 months of the application due date. On the application due date, candidates may not have completed more than 6 months of postdoctoral training.
TRANSLATIONAL MEDICINE AND THERAPEUTICS: The goal of the PhRMA Foundation's Translational Medicine and Therapeutics Program is to promote the development
and use of experimental and computational methods in an integrative approach towards clinical needs in diagnosis, treatment and prevention. This can involve enhanced understanding of human biological and disease processes but requires a strong translational component. This program will support the concepts of Translational Medicine and Therapeutics as defined by the Foundation: "Translational medicine and therapeutics is a discipline focused on bridging experimental and computational technologies and discoveries in the research laboratory to their application in clinical practice. Examples of research components include activities in molecular and cellular biology, pathophysiology, systems biology, bioinformatics, modeling and simulation, and other quantitative sciences to connect basic biological concepts and entities to directly address unmet medical needs. The goals are to use clinical observation as the basis for hypothesis generation to further basic research and to efficiently advance the product of basic research to patients." Translational Medicine and Therapeutics awards will advance
training and support career development of scientists engaged in research that significantly integrates cutting-edge technologies with advanced biological, chemical, and pharmacological sciences and engineering methodologies in such areas as (but not restricted to):
* Genetics (Molecular, Pharmaco-, Population, Medical)
* Genomics (Functional, Structural, Toxico-, Pharmaco-, Comparative)
* Systems (Biology and Pharmacology)
* Pathways and networks
* Integrative biology
* Modeling and simulation
* Target Identification and Validation
* Biomarker Discovery and Validation
* Vaccine Development
* Molecular Epidimiology
* Imaging
* Disease Modeling
The Edward N. & Della L. Thome Memorial Foundation was created in 2002 to advance the health of older adults through the support of direct service projects and medical research on diseases and disorders affecting older adults. In keeping with the Foundation's mission, the goal of the Awards Program is to support translational research that will lead to improved therapies for individuals suffering from age- related macular degeneration (AMD)
The purpose of the Kirschstein-NRSA predoctoral fellowship (F31) award is to enable promising predoctoral students to obtain individualized, mentored research training from outstanding faculty sponsors while conducting dissertation research in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The proposed mentored research training must reflect the applicants dissertation research project and is expected to clearly enhance the individuals potential to develop into a productive, independent research scientist.
The National Institutes of Health (NIH) awards senior individual research training fellowships to experienced scientists who wish to make major changes in the direction of their research careers or who wish to broaden their scientific background by acquiring new research capabilities as independent investigators in research fields relevant to the missions of participating NIH Institutes and Centers.
This prize is awarded to an individual for outstanding research in the field of behavioral neurology. Applicants should have a strong desire to expand the field of behavioral neurology through research.
Must have carried out independent research (clinical or basic) in the field of neuroendocrinology. Work must demonstrate a major point in neuroendocrinological science for any of the following:
Pathophysiology/basic mechanisms
Treatment paradigms
Illustrations of major comorbidity
This FOA relates to one of the initiatives of the SPARC (Stimulating Peripheral Activity to Relieve Conditions) Common Fund program titled: Use of Existing Market-Approved Technology for New Market Indications. By establishing effective public-private partnerships, this SPARC initiative allows supported investigators to have access to existing neuromodulation technology to explore new indications. A number of device manufacturers have entered into partnership agreements with the NIH to make their neuromodulation technology, consisting of implantable devices with recording and/or stimulation capabilities, available to SPARC's supported clinical investigators (see Device Portal for a list of companies and available technologies). The specific goal of this FOA is to promote the pre-clinical development of these technologies, in support of a new market indication, towards enabling an Investigational Device Exemption (IDE) submission for a future pilot clinical study. Awarded projects of this FOA that fully reach their pre-clinical testing milestones will be eligible for further support, subject to a subsequent FOA, to conduct a pilot clinical study. The expectation is that these pilot clinical studies will provide the initial proof-of-principle demonstrations in humans that will motivate the additional studies needed in pursuing FDA approval as a labeled indication.
This FOA relates to one of the initiatives of the SPARC (Stimulating Peripheral Activity to Relieve Conditions) Common Fund program titled: Use of Existing Market-Approved Technology for New Market Indications. By establishing effective public-private partnerships, this SPARC initiative allows supported investigators to have access to existing neuromodulation technology to explore new indications. A number of device manufacturers have entered into partnership agreements with the NIH to make their neuromodulation technology, consisting of implantable devices with recording and/or stimulation capabilities, available to SPARC's supported clinical investigators (see Device Portal for a list of companies and available technologies). The specific goal of this FOA is to promote the pre-clinical development of these technologies, in support of a new market indication, towards enabling an Investigational Device Exemption (IDE) submission for a future pilot clinical study. Awarded projects of this FOA that fully reach their pre-clinical testing milestones will be eligible for further support, subject to a subsequent FOA, to conduct a pilot clinical study. The expectation is that these pilot clinical studies will provide the initial proof-of-principle demonstrations in humans that will motivate the additional studies needed in pursuing FDA approval as a labeled indication.
The International Research Network Connections (IRNC) program supports high-performance network connectivity required by international science and engineering research and education collaborations involving the NSF research community. NSF expects to make 1-2 awards to link U.S. research networks with peer networks in Europe and Africa and leverage existing international network connectivity. High-performance network connections funded by this program are intended to support science and engineering research and education applications, and preference will be given to solutions that provide the best economy of scale and demonstrate the ability to support the largest communities of interest with the broadest services. Funded projects will assist the U.S. research and education community by enabling state-of-the-art international network services and access to increased collaboration and data services. Through extended international network connections, additional research and production network services will be enabled, complementing those currently offered or planned by domestic research networks.
The International Research Network Connections (IRNC) program supports high-performance network connectivity required by international science and engineering research and education collaborations involving the NSF research community. NSF expects to make 1-2 awards to link U.S. research networks with peer networks in Europe and Africa and leverage existing international network connectivity. High-performance network connections funded by this program are intended to support science and engineering research and education applications, and preference will be given to solutions that provide the best economy of scale and demonstrate the ability to support the largest communities of interest with the broadest services. Funded projects will assist the U.S. research and education community by enabling state-of-the-art international network services and access to increased collaboration and data services. Through extended international network connections, additional research and production network services will be enabled, complementing those currently offered or planned by domestic research networks.
CURE seeks to promote the careers of young investigators to allow them to develop a research focus independent of their mentor(s). Researchers may propose basic or clinical studies, but this award mechanism is not intended to support clinical trials. Research that involves collaboration and a multidisciplinary approach is desirable. Applicant will be required to discuss how this avenue of research is independent from his or her mentor's research, and will lead him or her to a path of independent epilepsy research.
The NIH Directors Early Independence Award Program supports exceptional investigators who wish to pursue independent research directly after completion of their terminal doctoral/research degree or clinical residency, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career.
These awards encourage and support scientists working on the development of novel and creative approaches to understanding brain function. The Endowment Fund is especially interested in how a new technology may be used or adapted to monitor, manipulate, analyze, or model brain function at any level, from the molecular to the entire organism.
The PRP IIRA supports highly rigorous, multidisciplinary, high-impact research projects that have the potential to make an important contribution to Parkinson's disease research and/or patient care. This award mechanism supports the full spectrum of research from basic science through clinical research that specifically focuses on scientific and clinical Parkinson's disease issues, which, if successfully addressed, have the potential to make a major impact in understanding, preventing, diagnosing, or treating Parkinson's disease or enhancing the well-being of individuals experiencing the impact of the disease.
The PRP IIRA supports highly rigorous, multidisciplinary, high-impact research projects that have the potential to make an important contribution to Parkinson's disease research and/or patient care. This award mechanism supports the full spectrum of research from basic science through clinical research that specifically focuses on scientific and clinical Parkinson's disease issues, which, if successfully addressed, have the potential to make a major impact in understanding, preventing, diagnosing, or treating Parkinson's disease or enhancing the well-being of individuals experiencing the impact of the disease.
The purpose of the NIDCD Research Career Enhancement Award for Established Investigators (K18) program is to enable established, proven investigators to augment or redirect their research programs through the acquisition of new research skills to answer questions relevant to the hearing, balance, smell, taste, voice, speech and language sciences.
The purpose of the NINDS Research Program Award (RPA) is to provide longer-term support and increased flexibility to Program Directors (PDs) /Principal Investigators (PIs) whose records of research achievement demonstrate their ability to make major contributions to neuroscience. RPAs will support the overall research programs of NINDS-funded investigators for up to 8 years, at a level commensurate with a PD/PIs recent NINDS support (Part 2, Section II) This greater funding stability will provide eligible investigators at nearly all career stages increased freedom and flexibility, allowing them to be more adventurous in their research, take greater risks, embark upon research that breaks new ground, undertake research projects that require a longer timeframe, and/or extend previous discoveries in new directions. Research supported through the RPA must be within the scope of the NINDS mission (http://www.ninds.nih.gov/about_ninds/mission.htm). Research activities outside of the NINDS mission, or traditionally supported by another NIH Institute or Center will not be considered through this program.
The purpose of the NINDS Research Program Award (RPA) is to provide longer-term support and increased flexibility to Program Directors (PDs) /Principal Investigators (PIs) whose records of research achievement demonstrate their ability to make major contributions to neuroscience. RPAs will support the overall research programs of NINDS-funded investigators for up to 8 years, at a level commensurate with a PD/PI's recent NINDS support (Part 2, Section II) This greater funding stability will provide eligible investigators at nearly all career stages increased freedom and flexibility, allowing them to be more adventurous in their research, take greater risks, embark upon research that breaks new ground, undertake research projects that require a longer timeframe, and/or extend previous discoveries in new directions. Research supported through the RPA must be within the scope of the NINDS mission
The NETP Program IIRA supports highly rigorous, multidisciplinary, high-impact research projects that have the potential to make an important contribution to neurotoxin exposure and treatment-related Parkinson's research. This award mechanism supports the full spectrum of research from basic science through clinical research.
Group items tagged 
